

May 5-7, 2003 • Crystal Gateway Marriott • Arlington, VA

# *The Sixth Annual Conference*


on

# Vaccine Research

- Basic Science
- Product Development
- Clinical & Field Studies

Call for Abstracts  
and Conference Announcement

SPONSORED BY:



NATIONAL FOUNDATION FOR INFECTIOUS DISEASES

IN COLLABORATION WITH:



Centers for Disease  
Control and Prevention



Center for Biologics  
Evaluation and Research  
Food and Drug Administration

CVD



Center for Vaccine  
Development,  
University of  
Maryland



International Society  
for Vaccines



International Vaccine  
Institute



National Institute of Allergy  
and Infectious Diseases



Albert B. Sabin  
Vaccine Institute



United States  
Department of  
Agriculture

# The Sixth Annual Conference

## Conference Overview

*The remarkable pace of biotechnology discovery is continuing unabated. New cytokines are identified, immune regulatory pathways unraveled, promising adjuvants reported, and investigational products revealed to have high degrees of protection for humans against viral diseases not yet vaccine preventable, such as human papilloma virus and herpes simplex. The tools of vaccination are being applied therapeutically for various cancers and chronic conditions.*

*The Annual Conference on Vaccine Research provides high-quality, current reports of scientific progress featured in both invited presentations and submitted abstracts. The disparate fields covered in both human and veterinary vaccinology encourage valuable cross-fertilization of ideas and approaches among researchers otherwise focused on specific diseases or methods.*

*The Conference has become the largest scientific meeting devoted exclusively to research on vaccines and associated technologies for disease prevention and treatment through immunization. The Sixth Annual Conference promises to maintain this tradition as the premier venue for cutting edge topics and issues. Leading international experts will lead seminars and panel discussions on topical areas of basic immunology, product development, clinical testing, regulation, and other aspects of vaccine research. Opportunities for networking and scientific collaboration critical to advancing vaccine science and development will be available through audience discussions, poster presentations, sponsored exhibits, and evening ceremonies and receptions.*

## CONFERENCE OBJECTIVES

At the conclusion of this conference, participants should be able to meet the following session-specific objectives:

### Keynote Address.

- Characterize the attributes and functions of effector and memory T cells

### Mary Lou Clements-Mann Memorial Lecture in Vaccine Sciences.

- Discuss the importance of overcoming financial obstacles and public relations challenges to conduct high-visibility phase III trials of vaccines in the absence of validated animal models or serologic correlates of protection.

### Long-term Impact of Vaccination Strategies on Disease Epidemiology

- Explain the predictions of mathematical models of the effect of vaccination programs on the epidemiology of vaccine-preventable diseases.
- Discuss the possibility that vaccination programs result in the selection of new or emerging serotypes of disease-causing organisms.
- Discuss unexpected observations with respect to the epidemiology of polio as they relate to the global effort to eradicate polio.

### Vaccines for Zoonotic Diseases

- Understand the role of vaccines in controlling leptospirosis in animals and the impact of vaccines in reducing exposure and incidence of human leptospirosis.
- Discuss the current status of vaccines in clinical trials to prevent or control Rift Valley fever in humans and animals.
- Describe the technology and use of live rabies vaccine in baits for wildlife and how this strategy has eliminated or greatly reduced rabies in wildlife populations.

### Vaccine Supply: Global Crisis

- Provide an overview of current trends in the worldwide supply and distribution of vaccines.
- Review factors that influenced shortfalls in vaccine supply in the U.S. during 2002, and recommendations for reducing the likelihood of future supply shortfalls.

- Discuss the opportunities and challenges facing vaccine developers in developing countries.

### Regulatory/Suppressor T Cells: Implications for Vaccinology

- Explain the characteristics and functions of regulatory and suppressor T cells.
- Describe the roles of regulatory T cells in virus- and bacteria-mediated diseases.
- Discuss the roles that regulatory T cells play in response to parasitic infections.

### Vaccines Against Nosocomial Infections

- Review scientific progress in the development of vaccines against *Staphylococcus aureus*.
- Discuss approaches to developing a vaccine against *Pseudomonas*.
- Review the status of research on vaccines against respiratory syncytial virus.
- Describe the state of development of vaccines against *Clostridium difficile*.

### Vaccines and Biodefense

- Describe approaches to managing the threat of bioterrorist attacks on agriculture.
- Identify new approaches to enhance the value and safety of vaccines against anthrax.
- Discuss new approaches to improving the safety profile of vaccines against smallpox.
- Evaluate evidence regarding the potential for weaponizing arenaviruses.

### Malaria Vaccines

- Discuss new approaches and developments in the quest for vaccines against malaria.

### Hot Topics in Immunology

- Discuss antigen-specific modulation of B cells.

# on Vaccine Research

## EXHIBIT HALL

*The conference will feature an exhibit hall.  
If you would like to obtain an Exhibitor Prospectus  
for your organization, please contact:*

**Sharon Cooper-Kerr**  
NFID (attn: ACVR Exhibits)  
4733 Bethesda Avenue, Suite 750 • Bethesda, MD 20814 USA  
Tel. 301-656-0003 x14 • Fax 301-907-0878  
E-Mail scooper-kerr@nfid.org

## WHO SHOULD ATTEND?

- Researchers and Scientists
- Molecular Biologists
- Epidemiologists
- Public Health Officials
- Microbiologists
- Physicians and Veterinarians
- Immunologists
- Vaccine Manufacturers

Conference participants should have a knowledge of or interest in vaccine research.

## ACKNOWLEDGMENTS (as of December 16, 2002)

This conference is supported, in part, through unrestricted educational grants from:

- Aventis Pasteur
- Becton Dickinson
- Bioject, Inc.
- Chiron Corporation
- Coley Pharmaceutical Group
- Dynport Vaccine Company
- MedImmune
- Merck Vaccine Division
- PowderJect Vaccines, Inc.
- U.S. Food and Drug Administration
- VaxGen
- Vical Incorporated
- Wyeth Pharmaceuticals

## CME ACCREDITATION STATEMENT

The National Foundation for Infectious Diseases (NFID) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education (CME) for physicians. NFID takes responsibility for the content, quality, and scientific integrity of this CME activity.

## CME CREDIT STATEMENT

The National Foundation for Infectious Diseases (NFID) designates this CME activity for a maximum of 20.3 credit hours in Category 1 of the Physician's Recognition Award of the American Medical Association. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

# The Sixth Annual Conference

## CONFERENCE CO-CHAIRS

**William J. Martone, M.D.**  
National Foundation  
for Infectious Diseases  
Bethesda, Maryland

**Peter L. Nara, D.V.M.,  
Ph.D.**  
Biological Mimetics, Inc.  
Frederick, Maryland

**N. Regina Rabinovich, M.D.**  
Program for Appropriate  
Technology in Health  
Rockville, Maryland

**Bruce G. Weniger, M.D.**  
Centers for Disease Control  
and Prevention  
Atlanta, Georgia

## CONFERENCE ORGANIZING COMMITTEE

**John D. Clemens, M.D.**  
International Vaccine Institute  
Seoul, Korea

**Marie-Paule Kieny, M.D.**  
World Health Organization  
Geneva, Switzerland

**Myron M. Levine, M.D.,  
D.T.P.H.**  
University of Maryland  
School of Medicine  
Baltimore, Maryland

**William J. Martone, M.D.**  
National Foundation  
for Infectious Diseases  
Bethesda, Maryland

**Pamela M. McInnes, D.D.S.**  
National Institute of Allergy  
and Infectious Diseases  
Bethesda, Maryland

**Peter L. Nara, D.V.M., Ph.D.**  
Biological Mimetics, Inc.  
Frederick, Maryland

**David A. Neumann, Ph.D.**  
National Foundation  
for Infectious Diseases  
Bethesda, Maryland

**Gregory A. Poland, M.D.**  
International Society for Vaccines  
Rochester, Minnesota

**N. Regina Rabinovich, M.D.**  
Program for Appropriate  
Technology in Health  
Rockville, Maryland

**Fran G. Sonkin**  
Albert B. Sabin Vaccine Institute  
Washington, D.C.

**David E. Swayne, D.V.M.,  
Ph.D.**  
U.S. Department of Agriculture  
Athens, Georgia

**Bruce G. Weniger, M.D.**  
Centers for Disease Control  
and Prevention  
Atlanta, Georgia

**Kathryn C. Zoon, Ph.D.**  
U.S. Food and Drug Administration  
Rockville, Maryland

## SCIENTIFIC PROGRAM COMMITTEE

**Jacques Banchereau, Ph.D.**  
Baylor Institute for Immunology Research  
Dallas, Texas

**Richard J. Duma, M.D.,  
Ph.D.**  
Halifax Medical Center  
Daytona Beach, Florida

**Diane E. Griffin, M.D.,  
Ph.D.**  
Johns Hopkins University Bloomberg  
School of Public Health  
Baltimore, Maryland

**Paul-Henri Lambert, M.D.**  
Centre Medical Universitaire de Genève  
Geneva, Switzerland

**Myron M. Levine, M.D.,  
D.T.P.H.**  
*Member, Conference Organizing  
Committee*

**William J. Martone, M.D.**  
*Member, Conference Organizing  
Committee*

**Gary J. Nabel, M.D., Ph.D.**  
National Institutes of Health  
Bethesda, Maryland

**Peter L. Nara, D.V.M., Ph.D.**  
*Member, Conference Organizing  
Committee*

**David A. Neumann, Ph.D.**  
*Member, Conference Organizing  
Committee*

**Stanley A. Plotkin, M.D.**  
Aventis Pasteur  
Doylestown, Pennsylvania

**N. Regina Rabinovich, M.D.**  
*Member, Conference Organizing  
Committee*

**Harriet L. Robinson, Ph.D.**  
Emory University  
Atlanta, Georgia

**Connie Schmaljohn, Ph.D.**  
U.S. Army Medical Research Institute  
of Infectious Diseases  
Ft. Detrick, Maryland

**Ethan M. Shevach, M.D.**  
National Institute of Allergy and

Infectious Diseases  
Bethesda, Maryland

**George R. Siber, M.D.**  
Wyeth Lederle Vaccines  
Pearl River, New York

**David E. Swayne, D.V.M.,  
Ph.D.**  
*Member, Conference Organizing  
Committee*

**Bruce G. Weniger, M.D.**  
*Member, Conference Organizing  
Committee*

**Kathryn C. Zoon, Ph.D.**  
*Member, Conference Organizing  
Committee*

## EXECUTIVE STAFF MEMBERS

**Sharon Cooper-Kerr**  
*Director, Events Planning*  
National Foundation  
for Infectious Diseases  
Bethesda, Maryland

**Sheena L. Majette**  
*Director, Continuing Medical Education*  
National Foundation  
for Infectious Diseases  
Bethesda, Maryland

**Len Novick**  
*Executive Director*  
National Foundation  
for Infectious Diseases  
Bethesda, Maryland

# on Vaccine Research

## PRELIMINARY PROGRAM\*

Sunday, May 4, 2003

7:00 p.m. - 9:00 p.m. REGISTRATION

Monday, May 5, 2003

7:00 a.m. - 9:00 a.m. REGISTRATION AND POSTER SET-UP

8:30 a.m. CONTINENTAL BREAKFAST

9:00 a.m. WELCOME AND INTRODUCTIONS

### KEYNOTE ADDRESS

9:10 a.m. EFFECTOR AND MEMORY T CELLS  
Antonio Lanzavecchia, M.D.  
*Institute for Research in Biomedicine*

9:45 a.m. QUESTIONS AND ANSWERS

### MARY LOU CLEMENTS-MANN MEMORIAL LECTURE IN VACCINE SCIENCES

9:50 a.m. LESSONS FROM THE WORLD'S FIRST PHASE-III  
FIELD EFFICACY TRIALS OF A PREVENTIVE AIDS  
VACCINE  
Donald Francis, M.D.  
*VaxGen, Inc.*

10:25 a.m. QUESTIONS AND ANSWERS

10:30 a.m. COFFEE BREAK

### SYMPOSIUM 1: LONG-TERM IMPACT OF VACCINATION STRATEGIES ON DISEASE EPIDEMIOLOGY

11:00 a.m. EPIDEMIOLOGICAL CHANGES FOLLOWING  
VACCINATION: WHAT DOES MATHEMATICAL  
MODELING SUGGEST MAY HAPPEN?  
Professor Roy M. Anderson  
*Imperial College*

11:25 a.m. QUESTIONS AND ANSWERS

11:30 a.m. PNEUMOCOCCAL CONJUGATE VACCINES:  
WHAT IS THE RISK OF POST VACCINATION  
EMERGING SEROTYPES AND REPLACEMENT DISEASE?  
Ron Dagan, M.D.  
*Ben-Gurion University*

11:55 a.m. QUESTIONS AND ANSWERS

12:00 p.m. SURPRISES IN POLIO EPIDEMIOLOGY  
AS ERADICATION NEARS  
Stephen C. Cochi, M.D.  
*Centers for Disease Control*

12:25 p.m. QUESTIONS AND ANSWERS

12:30 p.m. LUNCH

### SUBMITTED PRESENTATIONS

1:45 p.m. CONCURRENT SUBMITTED PRESENTATIONS

3:15 p.m. COFFEE BREAK

### SYMPOSIUM 2: VACCINES AND BIODEFENSE

3:45 p.m. AGRICULTURAL BIOTERRORISM:  
MANAGING THE THREAT  
Mark Wheelis, Ph.D.  
*University of California, Davis*

4:10 p.m. QUESTIONS AND ANSWERS

4:15 p.m. ANTHRAX: ISSUES AND SOLUTIONS  
Arthur M. Friedlander, M.D.  
*U.S. Army Medical Research Institute  
of Infectious Diseases*

4:40 p.m. QUESTIONS AND ANSWERS

4:45 p.m. NEW STRATEGIES FOR SAFER SMALLPOX VACCINES  
Barney S. Graham, M.D., Ph.D.  
*National Institutes of Health*

5:10 p.m. QUESTIONS AND ANSWERS

5:15 p.m. SOUTH AMERICAN ARENAVIRUSES:  
WILL THEY EMERGE AS THREATS?  
Clarence J. Peters, M.D.  
*University of Texas Medical Branch*

5:40 p.m. QUESTIONS AND ANSWERS

5:45 p.m. ADJOURNMENT

6:00 p.m. POSTER AND EXHIBIT RECEPTION

# Tuesday, May 6, 2003

7:00 a.m.- 8:00 a.m. REGISTRATION

7:30 a.m. CONTINENTAL BREAKFAST

## SYMPOSIUM 3: VACCINE SUPPLY: GLOBAL CRISIS

8:00 a.m. GLOBAL TRENDS AND ISSUES IN VACCINE SUPPLY  
Julie Milstien, Ph.D.  
*World Health Organization*

8:25 a.m. QUESTIONS AND ANSWERS

8:30 a.m. VACCINATION SUPPLY CRISES IN USA 2002:  
A GOVERNMENT PERSPECTIVE  
Bruce Gellin, M.D., M.P.H.  
*Department of Health and Human Services*

8:55 a.m. QUESTIONS AND ANSWERS

9:00 a.m. VACCINE SUPPLY CRISES IN THE USA 2002:  
AN INDUSTRY PERSPECTIVE  
Peter Paradiso, Ph.D.  
*Wyeth Vaccines and Nutrition*

9:25 a.m. QUESTIONS AND ANSWERS

9:30 a.m. SUPPLYING NEW DEVELOPING MARKET VACCINES:  
ROLE OF THE VACCINE INDUSTRY IN  
DEVELOPING COUNTRIES  
To Be Announced

9:55 a.m. QUESTIONS AND ANSWERS

10:00 a.m. COFFEE BREAK

## SYMPOSIUM 4: REGULATORY/SUPPRESSOR T CELLS: IMPLICATIONS FOR VACCINOLOGY

10:30 a.m. REGULATORY/SUPPRESSOR T CELLS: AN OVERVIEW  
Ethan M. Shevach, M.D.  
*National Institutes of Health*

10:55 a.m. QUESTIONS AND ANSWERS

11:00 a.m. REGULATORY T CELLS IN VIRAL AND BACTERIAL  
DISEASES  
Kingston Mills, Ph.D.  
*Trinity College, Dublin*

11:25 a.m. QUESTIONS AND ANSWERS

11:30 a.m. REGULATORY T CELLS IN PARASITIC DISEASES  
Yasmine Belkaid, M.D.  
*University of Cincinnati*

11:55 a.m. QUESTIONS AND ANSWERS

12:00 p.m. LUNCH

## SYMPOSIUM 5: VACCINES AGAINST NOSOCOMIAL INFECTIONS

1:15 p.m. UPDATE ON A VACCINE AGAINST  
STAPHYLOCOCCUS AUREUS  
Robert Daum, M.D.  
*University of Chicago*

1:40 p.m. QUESTIONS AND ANSWERS

1:45 p.m. TOWARDS THE DEVELOPMENT OF A  
PSEUDOMONAS VACCINE  
Gerald B. Pier, Ph.D.  
*Harvard Medical School*

2:10 p.m. QUESTIONS AND ANSWERS

2:15 p.m. UPDATE ON A VACCINE FOR RESPIRATORY  
SYNCYTIAL VIRUS  
Ruth Karron, M.D.  
*Johns Hopkins University*

2:40 p.m. QUESTIONS AND ANSWERS

2:45 p.m. DEVELOPMENT OF A VACCINE AGAINST  
CLOSTRIDIUM DIFFICILE  
Karen Kotloff, M.D.  
*University of Maryland*

3:10 p.m. QUESTIONS AND ANSWERS

3:15 p.m. COFFEE BREAK

## SUBMITTED PRESENTATIONS

3:45 p.m. CONCURRENT SUBMITTED PRESENTATIONS

5:30 p.m. ADJOURNMENT

6:00 p.m. ALBERT B. SABIN VACCINE INSTITUTE RECEPTION

7:00 p.m. PRESENTATION OF THE ALBERT B. SABIN  
GOLD MEDAL

# Wednesday, May 7, 2003

7:00 a.m.- 8:00 a.m. REGISTRATION  
7:30 a.m. CONTINENTAL BREAKFAST

## SYMPOSIUM 6: VACCINES FOR ZOOONOTIC DISEASES

8:00 a.m. NEW PARADIGMS OF LEPTOSPIRAL IMMUNITY AND IMPACT ON VACCINE DESIGN  
Carole Bolin, D.V.M., Ph.D.  
*Michigan State University*

8:30 a.m. QUESTIONS AND ANSWERS

8:40 a.m. CURRENT STATUS OF RIFT VALLEY FEVER VIRUS VACCINES  
John C. Morrill, D.V.M., Ph.D.  
*Orion Research and Management Services*

9:10 a.m. QUESTIONS AND ANSWERS

9:20 a.m. RABIES VACCINES: PAST, PRESENT AND FUTURE  
Charles Rupprecht, V.M.D., M.S., Ph.D.  
*Centers for Disease Control*

9:50 a.m. QUESTIONS AND ANSWERS

10:00 a.m. COFFEE BREAK

## SUBMITTED PRESENTATIONS

10:30 a.m. CONCURRENT SUBMITTED PRESENTATIONS

12:15 p.m. LUNCH

## SYMPOSIUM 7: MALARIA VACCINES

1:15 p.m. PROGRESS REPORT ON MALARIA VACCINES  
Ripley Ballou, M.D.  
*Medimmune, Inc.*

1:30 p.m. QUESTIONS AND ANSWERS

1:35 p.m. IMMUNE CORRELATES OF PROTECTION  
Adrian Hill, M.R.C.P., D.M., D.Phil. (invited)  
*Wellcome Trust Centre for Human Genetics*

1:50 p.m. QUESTIONS AND ANSWERS

1:55 p.m. TRANSLATING THE MALARIA GENOME  
Daniel J. Carucci, M.D., Ph.D.  
*United States Navy*

2:10 p.m. QUESTIONS AND ANSWERS

2:15 p.m. TRANSMISSION BLOCKING VACCINES  
Allan Saul, Ph.D.  
*National Institutes of Health*

2:30 p.m. QUESTIONS AND ANSWERS

2:35 p.m. PANEL DISCUSSION: ISSUES IN THE DESIGN OF MALARIA VACCINE FIELD TRIALS

3:15 p.m. ADJOURNMENT

## SYMPOSIUM 8: HOT TOPICS IN IMMUNOLOGY

3:45 p.m. ANTIGEN-SPECIFIC EARLY PRIMARY HUMORAL RESPONSES MODULATE IMMUNODOMINANCE OF B CELL EPITOPES  
Kanury V.S. Rao, Ph.D.  
*International Centre for Genetic Engineering and Biotechnology*

4:10 p.m. QUESTIONS AND ANSWERS

4:15 p.m. ORIGINAL ANTIGENIC SIN IMPAIRS CYTOTOXIC T LYMPHOCYTE RESPONSES TO VIRUSES BEARING VARIANT EPITOPES  
Rolf Zinkernagel, M.D., Ph.D. (invited)  
*Institute for Experimental Immunology*

4:40 p.m. QUESTIONS AND ANSWERS

4:45 p.m. MASS SPECTROMETRIC FINE DETERMINATION OF B CELL EPITOPES  
Kenneth Tomer, Ph.D. (invited)  
*National Institute of Environmental Health Sciences*

5:15 p.m. ADJOURNMENT

\* SPEAKERS AND PRESENTATIONS ARE SUBJECT TO CHANGE

# The Sixth Annual Conference

## Registration and Fees

### THE REGISTRATION FEES ARE AS FOLLOWS:

<i>On or before March 28, 2003*</i>	<b>\$350</b>
<i>After March 28, 2003 and Onsite</i>	<b>\$400</b>

*Registration Deadline – April 30, 2003 (registrations received after April 30 will be processed on-site)*

\*To qualify for the reduced registration fee of \$350, a **completed registration form with payment** must be **received** at the NFID office before 5 p.m. Eastern Time on March 28, 2003. Registrations or payments received after March 28 will be subject to the \$400 fee.

The registration fee includes a program/abstract book, continental breakfast on each day of the conference, coffee breaks, and receptions. Accommodations and additional meals are not included.

Follow the registration instructions below according to your method of payment. Confirmations will be sent within two weeks of completed registration and proper payment. **Please allow time for processing.**

- **Credit Cards:** If you are paying by credit card, you may register securely online at <http://www.nfid.org>, fax your registration to 1-301-907-0878 or mail it to the address below. We are unable to accept telephone registrations.
- **Check or Money Order:** Checks (drawn on a U.S. bank only) and/or money orders must be in U.S. dollars, made payable to **NFID**, and mailed with the registration form to the address below.

Purchase orders can not be accepted.

Send registrations to the following address:

**Sixth Annual Conference on Vaccine Research**  
National Foundation for Infectious Diseases  
4733 Bethesda Avenue, Suite 750  
Bethesda, MD 20814-5278 USA

*Registrations received after April 30  
will be processed on-site.*



## CANCELLATION POLICY

Refunds minus a \$75 administrative fee will be granted only if *written notification* arrives at the NFID office prior to 5 p.m. Eastern Time on April 4, 2003. There will be no refunds for cancellations made after April 4, 2003. NFID reserves the right to cancel this conference at any time. In the event of conference cancellation, only the full registration fee will be returned to the registrant.



# The Sixth Annual Conference

## General Information

### LANGUAGE

The official language for the conference is English.

### DATES AND LOCATION

The Sixth Annual Conference on Vaccine Research will be held May 5–7, 2003 at the following hotel:

**Crystal Gateway Marriott Hotel\***  
1700 Jefferson Davis Highway  
Arlington, Virginia 22202

*\*This facility is fully accessible to the public in accordance with the Americans with Disabilities Act guidelines.*

### HOTEL ACCOMMODATIONS

A limited number of guest rooms have been reserved at the Crystal Gateway Marriott Hotel for conference participants at the rate listed below:

\$169 (plus applicable taxes, currently 9.75%) per night, single occupancy.

To make a reservation, call the hotel directly at 703-920-3230 or the Marriott toll-free reservation department at 800-223-9290, and tell the agent that you are attending the *Annual Conference on Vaccine Research* being held from May 5-7, 2003.

Reservations should be made **no later than April 11, 2003** in order to secure the conference rate. After that date, rooms are on a space- and rate-available basis only. *Please note that the room block is limited, and contacting the hotel before April 11 does not guarantee that space will be available. Make your reservations as early as possible to avoid any problems.*

In addition, a small block of rooms has been reserved at the prevailing 2003 per diem for employees of the U.S. Federal Government. Identify yourself as a U.S. Government employee when you call to make your reservation. You will be required to present proof of your government employee status upon check-in.

## Instructions for Abstract Submission

The Scientific Program Committee invites submissions of abstracts of original research. Topic areas and abstract format are available on-line at the conference website. All abstracts must be submitted electronically. Abstracts should be submitted via the on-line submission program on the conference website ([www.nfid.org/conferences/vaccine03](http://www.nfid.org/conferences/vaccine03)).

**Deadline:** Abstracts must be received by February 17, 2003

**Notification:** Notification of Abstract acceptance will be e-mailed on or around March 10, 2003.

**Important Note:** Those whose abstracts are accepted for presentation must complete the conference registration form and pay the appropriate registration fee by March 28, 2003; otherwise the abstract(s) will be withdrawn. The conference does not have funds available to support travel or other costs, so please make financial arrangements as soon as possible. Presenters who fail to appear at the conference at the specified time(s) without making arrangements for a co-author to make their presentation will forfeit their registration fee and further abstract submissions will be automatically disqualified from consideration for two years.

**More Information:** For more information regarding the abstract submission process, please contact Ms. Sheena Majette through any of the following means:

Phone: 301-656-0003 ext. 12

Fax: 301-907-0878

E-Mail: [vaccine@nfid.org](mailto:vaccine@nfid.org)

# on Vaccine Research

## TRAVEL

### *By Plane:*

- Washington Ronald Reagan-National Airport (DCA) is located within 15 minutes of the hotel. The airport handles both domestic and international traffic. Taxi and Super Shuttle service is available.
- Dulles International Airport (IAD) is located approximately 28 miles from the hotel. Taxi and Super Shuttle service is available.
- Baltimore-Washington International Airport (BWI) is located approximately 55 miles from the hotel. Taxi and Super Shuttle service is available .

### *By Train:*

Amtrak Union Station is located 5 miles from the hotel. Shuttle service can be arranged through the hotel. Prices vary. A taxi will cost approximately \$15.

### *By Metro (subway):*

From Washington Ronald Reagan National Airport Metro Station, take the yellow line towards Mount Vernon Square. Get off at the Crystal City Metro Station. Follow the signs to the hotel.

From Union Station Metro Station take the red line towards Grosvenor or Shady Grove and get off at the Gallery Place Metro Station. Transfer to the yellow line towards Huntington. Get off at the Crystal City Metro Station. Follow the signs to the hotel.

### *By Car:*

**From North:** Take I-95 South over the Woodrow Wilson Bridge, take the 2nd exit to Route 1 North. Follow Rt. 1 north to Crystal City. Turn left on 23rd St. At the next traffic light turn right on Eads St. The hotel is two blocks up on the right.

**From the South:** Take I-95 North to I-395 North. Turn left on Jefferson Davis Highway (Route 1 South) to Crystal City and Airport (exit 9). Continue through the stoplight to the intersection at Eads Street. Turn left onto Eads Street. The hotel entrance is on the right.

**From Downtown D.C.:** Take 14th Street South following signs to I-395 South. Cross the Potomac River, then take the left exit for Route 1 South to Crystal City and Alexandria. Take the 15th Street exit and turn right at the end of the exit ramp. Turn left onto Eads Street. The hotel is a half block up on the left.

*If you require more detailed directions, please contact the hotel directly at 703-920-3230.*

**Parking at the Hotel:** Parking (valet or self-park) for overnight guests is approximately \$12. Daily parking rate is also \$14 per day and is based upon availability. Additional hourly parking lots are located nearby. For more information call 703-920-3230.

## RECOMMENDED DRESS

Business attire is appropriate for the sessions and receptions.

**Reminder:** Meeting room temperatures and personal comfort levels vary widely. Because meeting rooms often seem cold, please bring a sweater or jacket.

## INTERNATIONAL ATTENDEES

If you require a letter of invitation in order to obtain a visa for entry into the United States, please let us know as soon as possible. Please indicate where the letter should be sent and how it should be sent (fax, post, etc.)

## FINANCIAL SUPPORT

Please note that the conference does **not** have funds available to support registration, travel, or any other costs of registrants. Reductions in registration fees are **not** available except for the early registration fee.

*The Sixth Annual Conference*  
on Vaccine Research

National Foundation for Infectious Diseases  
4733 Bethesda Avenue, Suite 750  
Bethesda, MD 20814-5278 USA

Non-Profit Org.  
U.S. Postage  
PAID  
Frederick, MD  
Permit No. 110